Management of viral hepatitis B［J］. J Gastroenterol Hepatol, 2002,17(Suppl):S125-S145.
　　［2］von Weizsacker F, Kock J, Wieland S, et al. Dominant negative mutants of the duck hepatitis B virus core protein interfere with RNA pregenome packaging and viral DNA synthesis［J］. Hepatology, 1999,30(1):308-315.
　　［3］von Weizsacker F, Wieland S, Kock J, et al. Gene therapy for chronic viral hepatitis: Ribozymes, antisense oligonucleotides, and dominant negative mutants［J］. Hepatology,1997,26(2):251-255.
　　［4］Scaglioni P, Melegari M, Takahashi M, et al. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents［J］. Hepatology,1996,24(5):1010-1017.
　　［5］von Weizsacker F, Wieland S, Blum HE. Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein［J］. Hepatology,1996,24(2):294-299.
　　［6］Scaglioni PP, Melegari M, Wands JR. Characterization of hepatitis B virus core mutants that inhibit viral replication［J］. Virology,1994,205(1):112-120.
　　［7］Elliott G, OHare P. Intercellular tranfficking and protein delivery by a herpesvirus structural protein［J］. Cell, 1997,88:223-233.
　　［8］Schwarze SR, Dowdy SF. In vivo protein transduction: Intracellular delivery of biologically active proteins, compounds and DNA ［J］. Trends  Pharmacol Sci,2000,21:45-48.
　　［9］Ling R, Mutimer D, Ahmed M. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine ［J］. Hepatology, 1996,24:711-713.
　　［10］Tipples GA, Ma MM, Fischer KP. Mutations in HBV RNAdependent DNA polymerase confers resistance to lamivudine in vivo［J］. Hepatology, 1996,24:714-717.
　　［11］Guha C, Shah SJ, Ghosh SS, et al. Molecular therapies for viral hepatitis［J］. Biol Drugs, 2003,17:81-91

上一页  [1] [2] [3] [4]